Molecular targeting of the PKC-β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression

Hematological Oncology

Volumn 27, Issue 1, 2009, Pages 23-30

  Verdelli, Donata ^a   Nobili, Lucia ^a   Todoerti, Katia ^a   Intini, Daniela ^a   Cosenza, Maria ^b   Civallero, Monica ^b   Bertacchini, Jessika ^b   Deliliers, Giorgio Lambertenghi ^a   Sacchi, Stefano ^b   Lombardi, Luigia ^a   Neri, Antonino ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cell line; Enzastaurin; Gene expression profiling; Molecular pathway; Multiple myeloma

Indexed keywords

ADRENOMEDULLIN; B CELL MATURATION ANTIGEN; BETA TUBULIN; BETA7 INTEGRIN; CATHEPSIN B; CELL CYCLE PROTEIN 20; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; ENZASTAURIN; FIBRONECTIN; GLYCINE DEHYDROGENASE (DECARBOXYLATING); GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HEME OXYGENASE 1; INTERFERON REGULATORY FACTOR 4; LEGUMAIN; LIMBIC SYSTEM ASSOCIATED MEMBRANE PROTEIN; MARCKS PROTEIN; MYC PROTEIN; PADGEM PROTEIN; PARVALBUMIN; PROTEIN BCL 2; PROTEIN KINASE C BETA; PROTEIN MD 2; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; SUCCINATE SEMIALDEHYDE DEHYDROGENASE; THIOREDOXIN INTERACTING PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; INDOLE DERIVATIVE; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4; PROTEIN KINASE C;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IC 50; IMMUNE RESPONSE; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; UPREGULATION; WESTERN BLOTTING; CELL CYCLE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; ONCOGENE MYC; PATHOLOGY; TUMOR CELL LINE;

CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; INDOLES; INTERFERON REGULATORY FACTORS; MULTIPLE MYELOMA; PROTEIN KINASE C;

EID: 65249135021     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.875     Document Type: Article

References (18)

1. Hsu J, Shi Y, Krajewski S, et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001; 98: 2853-2855.
2. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C beta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65: 7462-7469.
3. Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007; 109: 1669-1677.
4. Rizvi MA, Ghias K, Davies KM, et al. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006; 5: 1783-1789.
5. Neri A, Marmiroli S, Tassone P, et al. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma 2008; 49: 1374-1383.
6. Mattioli M, Agnelli L, Fabris S, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005; 24: 2461-2473.
7. Agnelli L, Bicciato S, Mattioli M, et al. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 2005; 23: 7296-7306.
8. Schadt EE, Li C, Ellis B, Wong WH. Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J Cell Biochem Suppl 2001; 84: 120-125.
9. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148-3157.
10. Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006; 66: 6675-6682.
11. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-1667.
12. Klein U, Casola S, Cattoretti G, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 2006; 7: 773-782.
13. Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 2006; 25: 225-236.
14. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226-231.
15. Kataoka K, Fujiwara KT, Noda M, Nishizawa M. MafB, a new Maf family transcription activator that can associate with Maf and Fos but not with Jun. Mol Cell Biol 1994; 14: 7581-7591.
16. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5: 235-246.
17. Ryan MC, Hering M, Peckham D, et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther 2007; 6: 3009-3018.
18. Sutherland AP, Mackay F, Mackay CR. Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. Pharmacol Ther 2006; 112: 774-786.